On February 16, 2012 Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, reported that it received approval at yesterday’s special meeting of stockholders to change its corporate name to Synthetic Biologics, Inc (Press release, Synthetic Biologics, FEB 16, 2012, View Source [SID:1234510738]). It is expected that the Company’s shares will start trading under its new name and stock ticker symbol, "SYN", effective as of market open today, Thursday, February 16, 2012. Synthetic Biologics’ common stock has been assigned a new CUSIP number of 87163U102 in connection with the name change. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the special meeting, the Company filed an amendment to its Articles of Incorporation with the Nevada Secretary of State to effect the name change.